Neurogene develops genetic medicines for rare neurological diseases, with its lead candidate aimed at Rett syndrome. It last closed at $23.10 on Nov 17, down 0.86% on the day. The average 12-month price target from 2 analysts is $60.00 (+159.7% from the last close), with a high of $60.00 and a low of $60.00.
Only 2 firms rated NGNE in the past 90 days, not enough for a consensus
Average 12-month target
$60.00
▲ 159.7% upside
Based on 2 analysts who set a price target on NGNE in the past 90 days. The average target is $60.00, with a high of $60.00 and a low of $60.00, compared with the last close of $23.10.
Low $60.00Avg $60.00High $60.00
Blue marker: last close $23.10
Highest target$60.00
Average target$60.00
Lowest target$60.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 10Buy$65 → $60
JP MorganInitiated
Oct 8Buy$60
Canaccord GenuityMaintained
Aug 12Buy$166
GuggenheimMaintained
Aug 12Buy$81
HC Wainwright & Co.Maintained
Aug 12Buy$65
Date
Firm
Action
Rating
Price target
Nov 10
HC Wainwright & Co.
Target lowered
Buy
$65 → $60
Oct 8
JP Morgan
Initiated
Buy
$60
Aug 12
Canaccord Genuity
Maintained
Buy
$166
Aug 12
Guggenheim
Maintained
Buy
$81
Aug 12
HC Wainwright & Co.
Maintained
Buy
$65
Loading…
Technical Analysis
NGNE · as of the Nov 17 close · updated after every close
Downtrend
The stock is 11% below its 20 day and 20% below its 50 day average. It is 22% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38). The nearest support is the swing low (Oct 23) at $23.08, and the nearest resistance the Pivot R1 at $23.55.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNormal
VolatilityNormal, 9.1%/day
Key levels
$43.6652 week high+89.0%
$32.07100 day average+38.8%
$28.22200 day average+22.2%
$27.6150 day average+19.5%
$26.94Swing high (Oct 21)+16.6%
$25.6820 day average+11.2%
$23.55Pivot R1+1.9%
$23.10Last close
$23.08Swing low (Oct 23)−0.1%
$22.87Pivot−1.0%
$22.43Pivot S1−2.9%
$15.9352 week low−31.0%
Indicators
RSI (14)
38.49
Weak, oversold below 30
Neutral
MACD
-1.00
Below its signal line
Bearish
Stochastic
9.5
Near the bottom of its range
Oversold
ADX (14)
15.9
No clear trend
Williams %R
-90.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-128.9
Oversold below −100, overbought above 100
Oversold
Rate of change
−13.4%
Change over 10 sessions
Bearish
ATR (14)
$2.11
Typical daily range, 9.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Pullback inside a longer uptrend
Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 21.2%/day
Key levels
$43.6652 week high+89.0%
$32.07100 day average+38.8%
$28.22200 day average+22.2%
$27.6150 day average+19.5%
$26.94Swing high (Oct 21)+16.6%
$25.6820 day average+11.2%
$23.55Pivot R1+1.9%
$23.10Last close
$23.08Swing low (Oct 23)−0.1%
$22.87Pivot−1.0%
$22.43Pivot S1−2.9%
$15.9352 week low−31.0%
Indicators
RSI (14)
40.39
Middle of its range
Neutral
MACD
-1.39
Below its signal line
Bearish
Stochastic
14.6
Near the bottom of its range
Oversold
ADX (14)
24.8
Weak trend
Williams %R
-90.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-109.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−34.9%
Change over 10 sessions
Bearish
ATR (14)
$4.90
Typical daily range, 21.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Above
MA 200Below
What happened before, for NGNE
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how NGNE did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow NGNE usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How NGNE has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether NGNE is in one of them and how their past NGNE trades turned out.
Neurogene is a biotechnology company based in New York that develops genetic medicines for rare neurological diseases. Its lead product candidate, NGN-401, is being studied for Rett syndrome, a severe disease that affects brain development. The company uses its proprietary EXACT technology to control how much therapeutic gene is produced in key areas of the brain. None of its products are approved for sale yet, so it does not currently generate product revenue.